Resources

Sign-up to receive PDF versions of the following publications. When you sign up you will automatically be sent an email with download links for all the resources below. The case studies on the right are available to view immediately without an email sign-up.

Sign-up to Download the PDFs
Once you sign up you will be directed to a download page with all of the free Featured Resources on this page. We care about your privacy. We will not sell, rent, or give out your email address unless required to do so by law.

Presentation: High-Throughput Sequencing Market Potential

Presented at Discovery to Diagnostics 2007
Market Potential of Next Generation High Throughput Sequencing Technologies
by Richard Fisler | September 2007

The advent of next generation sequencing technologies has sparked considerable interest from all corners of the life science community - academic and pharmaceutical research, investors, tools providers and the general public. While the $1000 genome is not within reach of current high throughput systems, increased throughput and decreased cost enables novel applications and therefore increased market potential for sequencing systems.

Sign-up to Download the PDF
Once you sign up you will be directed to a download page with all of the free Featured Resources on this page. We care about your privacy. We will not sell, rent, or give out your email address unless required to do so by law.

Presentation: Chips to Hits 2006

Beyond Expression Arrays: New Applications Drive Market Growth
by Richard Fisler | September 2006

Expression arrays are a staple in the drug discovery process. However, new applications of array technology are emerging as expression data alone is not enough to adequately profile disease and therapeutics. Array-based SNP, CGH, ChIP-on-Chip, splice variants and resequencing analyses are delivering more in-depth information about cellular states and behaviors. This talk presents the current state of the market for these new technologies in the context of the overall array market, present drivers and barriers for adoption.

Sign-up to Download the PDF
Once you sign up you will be directed to a download page with all of the free Featured Resources on this page. We care about your privacy. We will not sell, rent, or give out your email address unless required to do so by law.

White Paper:
The Biotech BS Detector:
Ten Things We Remember Them Saying While on Their Way to Bankruptcy Court

by Rich Fisler, Gary Sams, Ph.D. | September 2006

Failed start-ups. One of the unavoidable facts of life in the biotech fast lane. In our view, there is really only one acceptable reason for a biotech company to fail - that the technology was not able to be developed into the product due to technical limitations. All other reasons why companies fail are fully avoidable as they are typically due to poor planning, naiveté or just plain blind ego.